Jia Xiaoxia, Guo Ting, Li Zhemin, Zhang Meng, Feng Yi, Dong Bin, Li Zhongwu, Hu Ying, Li Ziyu, Xing Xiaofang, Jia Shuqin, Ji Jiafu
Department of Molecular Diagnosis, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Department of Gastrointestinal Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Front Oncol. 2021 Jan 8;10:586752. doi: 10.3389/fonc.2020.586752. eCollection 2020.
Epstein-Barr virus-associated gastric cancer(EBVaGC)has a unique tumor immune microenvironment. We performed a comprehensive analysis of the tumor-infiltrating immune cells in a cohort of EBVaGC in a Chinese population.
Epstein-Barr encoding region (EBER) hybridization was performed in 1,328 consecutive cases of surgically resected GC. Densities of immune cells, including T cells, B cells, natural killer cells, and macrophages from the patients were calculated after immunohistochemical staining with CD3, CD20, CD57, and CD68 antibodies in tissue microarrays, respectively.
EBVaGC patients accounted for 4.1% (55 of 1,328) cases in the overall population. The average age of patients with EBVaGC was lower than that of non-EBVaGC patients. Histologically, EBVaGC patients exhibited poorly differentiated adenocarcinoma (P = 0.004) and lower frequency of vascular invasion (P = 0.034). The density of CD3 T lymphocytes (CD3, 23.84 ± 14.49 12.76 ± 8.93, P < 0.001) and CD68 macrophages (CD68, 9.73 ± 5.25 5.44 ± 4.18, P < 0.001) was significantly higher in EBVaGC patients. CD3 T cell density predicted better 5-year overall survival of EBVaGC patients (P = 0.022).
EBVaGC patients were younger with low-differentiated adenocarcinoma and less vascular invasion. Increased infiltration of multiple immune cells affected the prognosis of patients, especially EBVaGC patients with more CD3 T lymphocytes, who survived longer.
爱泼斯坦-巴尔病毒相关胃癌（EBVaGC）具有独特的肿瘤免疫微环境。我们对一组中国人群的EBVaGC患者的肿瘤浸润免疫细胞进行了全面分析。
对1328例连续手术切除的胃癌病例进行爱泼斯坦-巴尔病毒编码区（EBER）杂交。分别用CD3、CD20、CD57和CD68抗体对组织芯片进行免疫组化染色后，计算患者体内T细胞、B细胞、自然杀伤细胞和巨噬细胞等免疫细胞的密度。
EBVaGC患者占总人群的4.1%（1328例中的55例）。EBVaGC患者的平均年龄低于非EBVaGC患者。组织学上，EBVaGC患者表现为低分化腺癌（P = 0.004），血管侵犯频率较低（P = 0.034）。EBVaGC患者的CD3 T淋巴细胞密度（CD3，23.84±14.49对12.76±8.93，P < 0.001）和CD68巨噬细胞密度（CD68，9.73±5.25对5.44±4.18，P < 0.001）显著更高。CD3 T细胞密度预测EBVaGC患者5年总生存率更好（P = 0.022）。
EBVaGC患者较年轻，腺癌分化程度低，血管侵犯较少。多种免疫细胞浸润增加影响患者预后，尤其是CD3 T淋巴细胞较多的EBVaGC患者生存期更长。
